This S&P BSE 200 Stock has announced the inauguration of a new plant that will be commissioned for production by Q4 FY24. The company has a market cap of Rs. 53,813 crore and is 1% away from its 52 week high, trading at Rs. 918.40 versus Rs. 909.10 at previous close.
The company’s shareholding comprises 52% by the promoters, 24% by FIIs, 16% by DIIs and the rest being held by the public.
Aurobindo Pharma Ltd (“Aurobindo”) is also a multibagger YTD, returning 110%. Meaning, if you invested Rs. 1 lakh into Aurobindo at the start of this year, it would now be worth approx. Rs. 2.1 lakh! Further, the company stock has returned 77% in the last 1 year period.
In a filing dated 16th October 2023, the company stated its inauguration of the greenfield manufacturing Unit located at Plot numbers 1 and 2, Aurobindo Pharma Industrial Park, Parawada, Phase III, Vizag, Andhra Pradesh – of Eugia Steriles Private Ltd, a 100% subsidiary of Eugia Pharma Specialities Limited and a step-down subsidiary of Aurobindo.
This Unit will manufacture general injectables and expected to supply globally in phases. The project cost of the Unit is approx. Rs. 600 crores and the commercial production will be commenced during Q4 of FY24 in phases and subject to receipt of the necessary regulatory approvals from India as well as USA and the same will be disclosed in due course from time to time.
Aurobindo engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. In FY23, the company’s revenue grew 60% YoY from Rs. 11108 crore to Rs. 17728 crore. Net profits during the same period grew 17% YoY from Rs. 2783 crore to Rs. 3268 crore. This indicates a margin contraction of 650 bps.
Written by Sandeep R
